Enlivex Historical Balance Sheet

ENLV Stock

USD 1.05 0.04 3.67%

Trend analysis of Enlivex Therapeutics balance sheet accounts such as Total Current Liabilities of 3.6 M or Total Stockholder Equity of 25.2 M provides information on Enlivex Therapeutics' total assets, liabilities, and equity, which is the actual value of Enlivex Therapeutics to its prevalent stockholders. By breaking down trends over time using Enlivex Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Enlivex Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Enlivex Therapeutics is a good buy for the upcoming year.

Enlivex Therapeutics Inventory

(276,517)

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.

About Enlivex Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Enlivex Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Enlivex Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Enlivex Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Enlivex currently owns. An asset can also be divided into two categories, current and non-current.

Enlivex Therapeutics Balance Sheet Chart

At this time, Enlivex Therapeutics' Common Stock Shares Outstanding is fairly stable compared to the past year. Other Stockholder Equity is likely to climb to about 167.8 M in 2025, whereas Other Current Liabilities is likely to drop slightly above 2.4 M in 2025.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Enlivex Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Enlivex Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Enlivex Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Enlivex Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Enlivex Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Enlivex Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.At this time, Enlivex Therapeutics' Common Stock Shares Outstanding is fairly stable compared to the past year. Other Stockholder Equity is likely to climb to about 167.8 M in 2025, whereas Other Current Liabilities is likely to drop slightly above 2.4 M in 2025.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	4.0M	4.9M	4.4M	2.4M
Total Assets	67.6M	36.8M	33.1M	30.6M

Other Current Liab Total Assets

Enlivex Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Accounts Payable	Cash	Other Assets	Short Term Investments	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Treasury Stock	Long Term Debt	Good Will	Preferred Stock Total Equity	Other Liab	Net Debt	Retained Earnings	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Current Assets
Total Assets		0.5	0.73	1.0	0.73	0.5	0.45	0.45	-0.33	0.8	0.59	0.42	0.34	0.01	0.56	0.57	-0.56	0.76	-0.31	-0.22	0.63	0.11	0.4	0.41	0.37	0.61
Other Current Liab	0.5		0.93	0.45	0.22	0.21	0.64	0.21	-0.58	0.83	0.06	0.77	0.59	0.29	0.01	0.04	-0.01	0.63	-0.16	-0.64	0.55	0.57	0.8	0.75	0.63	0.55
Total Current Liabilities	0.73	0.93		0.69	0.53	0.4	0.74	0.2	-0.54	0.91	0.31	0.7	0.63	0.24	0.25	0.29	-0.25	0.76	-0.28	-0.58	0.55	0.44	0.71	0.69	0.6	0.57
Total Stockholder Equity	1.0	0.45	0.69		0.75	0.48	0.41	0.45	-0.29	0.76	0.63	0.36	0.3	-0.02	0.6	0.6	-0.6	0.73	-0.28	-0.17	0.59	0.08	0.34	0.36	0.32	0.57
Accounts Payable	0.73	0.22	0.53	0.75		0.49	0.46	0.0	-0.01	0.45	0.7	0.04	0.27	-0.01	0.65	0.7	-0.66	0.48	-0.28	-0.02	0.08	-0.09	0.0	0.04	0.1	0.18
Cash	0.5	0.21	0.4	0.48	0.49		0.35	-0.25	-0.26	0.55	0.12	0.17	0.22	-0.23	0.18	0.09	-0.18	0.33	-0.96	-0.13	0.38	0.09	0.16	0.18	0.2	0.38
Other Assets	0.45	0.64	0.74	0.41	0.46	0.35		-0.03	-0.27	0.64	0.28	0.63	0.91	0.47	0.16	0.3	-0.16	0.82	-0.22	-0.73	0.24	-0.15	0.58	0.65	0.64	0.25
Short Term Investments	0.45	0.21	0.2	0.45	0.0	-0.25	-0.03		0.12	0.38	-0.06	0.47	0.16	0.23	-0.12	-0.02	0.12	0.44	0.24	-0.2	0.67	0.07	0.45	0.47	0.41	0.66
Other Current Assets	-0.33	-0.58	-0.54	-0.29	-0.01	-0.26	-0.27	0.12		-0.55	-0.03	-0.5	-0.31	-0.1	0.01	-0.06	-0.01	-0.37	0.24	0.52	-0.43	-0.42	-0.53	-0.49	-0.49	-0.35
Total Liab	0.8	0.83	0.91	0.76	0.45	0.55	0.64	0.38	-0.55		0.15	0.79	0.62	0.19	0.1	0.16	-0.1	0.83	-0.47	-0.61	0.8	0.41	0.78	0.78	0.72	0.79
Intangible Assets	0.59	0.06	0.31	0.63	0.7	0.12	0.28	-0.06	-0.03	0.15		-0.23	0.03	-0.09	0.97	0.95	-0.97	0.32	0.16	0.28	-0.23	-0.22	-0.24	-0.23	-0.29	-0.27
Common Stock	0.42	0.77	0.7	0.36	0.04	0.17	0.63	0.47	-0.5	0.79	-0.23		0.82	0.56	-0.36	-0.13	0.36	0.77	-0.19	-0.86	0.76	0.24	0.99	1.0	0.93	0.74
Property Plant Equipment	0.34	0.59	0.63	0.3	0.27	0.22	0.91	0.16	-0.31	0.62	0.03	0.82		0.67	-0.15	0.13	0.14	0.83	-0.15	-0.87	0.38	-0.16	0.77	0.84	0.84	0.39
Treasury Stock	0.01	0.29	0.24	-0.02	-0.01	-0.23	0.47	0.23	-0.1	0.19	-0.09	0.56	0.67		-0.3	-0.04	0.3	0.43	0.24	-0.57	0.15	-0.16	0.52	0.57	0.6	0.18
Long Term Debt	0.56	0.01	0.25	0.6	0.65	0.18	0.16	-0.12	0.01	0.1	0.97	-0.36	-0.15	-0.3		0.88	-1.0	0.2	0.1	0.4	-0.24	-0.16	-0.36	-0.36	-0.43	-0.29
Good Will	0.57	0.04	0.29	0.6	0.7	0.09	0.3	-0.02	-0.06	0.16	0.95	-0.13	0.13	-0.04	0.88		-0.88	0.38	0.19	0.19	-0.22	-0.23	-0.15	-0.13	-0.19	-0.26
Preferred Stock Total Equity	-0.56	-0.01	-0.25	-0.6	-0.66	-0.18	-0.16	0.12	-0.01	-0.1	-0.97	0.36	0.14	0.3	-1.0	-0.88		-0.2	-0.1	-0.4	0.24	0.16	0.36	0.36	0.43	0.29
Other Liab	0.76	0.63	0.76	0.73	0.48	0.33	0.82	0.44	-0.37	0.83	0.32	0.77	0.83	0.43	0.2	0.38	-0.2		-0.19	-0.71	0.62	-0.08	0.71	0.78	0.76	0.59
Net Debt	-0.31	-0.16	-0.28	-0.28	-0.28	-0.96	-0.22	0.24	0.24	-0.47	0.16	-0.19	-0.15	0.24	0.1	0.19	-0.1	-0.19		0.16	-0.43	-0.17	-0.18	-0.2	-0.23	-0.44
Retained Earnings	-0.22	-0.64	-0.58	-0.17	-0.02	-0.13	-0.73	-0.2	0.52	-0.61	0.28	-0.86	-0.87	-0.57	0.4	0.19	-0.4	-0.71	0.16		-0.54	-0.03	-0.82	-0.88	-0.95	-0.55
Cash And Short Term Investments	0.63	0.55	0.55	0.59	0.08	0.38	0.24	0.67	-0.43	0.8	-0.23	0.76	0.38	0.15	-0.24	-0.22	0.24	0.62	-0.43	-0.54		0.32	0.75	0.75	0.73	0.97
Net Receivables	0.11	0.57	0.44	0.08	-0.09	0.09	-0.15	0.07	-0.42	0.41	-0.22	0.24	-0.16	-0.16	-0.16	-0.23	0.16	-0.08	-0.17	-0.03	0.32		0.32	0.2	0.1	0.35
Common Stock Total Equity	0.4	0.8	0.71	0.34	0.0	0.16	0.58	0.45	-0.53	0.78	-0.24	0.99	0.77	0.52	-0.36	-0.15	0.36	0.71	-0.18	-0.82	0.75	0.32		0.98	0.89	0.73
Common Stock Shares Outstanding	0.41	0.75	0.69	0.36	0.04	0.18	0.65	0.47	-0.49	0.78	-0.23	1.0	0.84	0.57	-0.36	-0.13	0.36	0.78	-0.2	-0.88	0.75	0.2	0.98		0.94	0.73
Other Stockholder Equity	0.37	0.63	0.6	0.32	0.1	0.2	0.64	0.41	-0.49	0.72	-0.29	0.93	0.84	0.6	-0.43	-0.19	0.43	0.76	-0.23	-0.95	0.73	0.1	0.89	0.94		0.75
Total Current Assets	0.61	0.55	0.57	0.57	0.18	0.38	0.25	0.66	-0.35	0.79	-0.27	0.74	0.39	0.18	-0.29	-0.26	0.29	0.59	-0.44	-0.55	0.97	0.35	0.73	0.73	0.75

Click cells to compare fundamentals

Enlivex Therapeutics Account Relationship Matchups

Enlivex Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	40.4M	95.1M	67.6M	36.8M	33.1M	30.6M
Other Current Liab	3.7M	3.2M	4.0M	4.9M	4.4M	2.4M
Total Current Liabilities	4.4M	4.7M	6.6M	6.1M	5.5M	3.6M
Total Stockholder Equity	35.5M	85.0M	56.8M	30.1M	27.1M	25.2M
Accounts Payable	463K	878K	1.9M	827K	744.3K	1.1M
Cash	5.7M	11.2M	47.8M	813K	935.0K	888.2K
Short Term Investments	30.0M	72.9M	299K	26.5M	30.5M	32.0M
Other Current Assets	2.4M	2.3M	1.4M	6.4M	7.4M	3.8M
Total Liab	4.9M	10.1M	10.8M	6.7M	6.1M	5.5M
Common Stock	1.6M	2.1M	2.1M	2.1M	2.5M	2.6M
Property Plant Equipment	1.1M	2.1M	2.5M	14.9M	17.1M	18.0M
Net Debt	(5.5M)	(10.6M)	(43.0M)	219K	197.1K	207.0K
Retained Earnings	(37.5M)	(52.0M)	(83.0M)	(112.1M)	(100.9M)	(95.8M)
Cash And Short Term Investments	35.7M	84.1M	48.1M	27.3M	31.4M	23.0M
Net Receivables	1.2M	1.1M	647K	229K	263.4K	250.2K
Common Stock Shares Outstanding	13.2M	17.9M	18.4M	18.6M	21.4M	22.4M
Liabilities And Stockholders Equity	40.4M	95.1M	67.6M	36.8M	42.4M	31.4M
Other Stockholder Equity	70.4M	133.8M	136.6M	138.9M	159.8M	167.8M
Total Current Assets	38.1M	86.4M	52.3M	33.8M	38.8M	28.5M
Property Plant And Equipment Net	2.1M	8.2M	14.9M	2.6M	3.0M	3.0M
Non Current Assets Total	2.2M	8.7M	15.3M	3.1M	3.5M	3.2M
Non Currrent Assets Other	8K	482K	105K	179K	205.9K	216.1K
Property Plant And Equipment Gross	2.1M	10.2M	18.4M	6.6M	7.6M	4.3M
Accumulated Other Comprehensive Income	(2.3M)	(1.3M)	977K	1.1M	1.3M	1.3M
Non Current Liabilities Total	499K	5.4M	4.2M	686K	788.9K	1.4M
Net Tangible Assets	11.3M	35.5M	85.0M	56.8M	65.4M	32.8M
Net Invested Capital	35.5M	85.0M	56.8M	30.1M	34.6M	36.3M
Net Working Capital	33.7M	81.7M	45.7M	27.7M	31.9M	33.3M
Capital Stock	1.6M	2.1M	2.1M	2.1M	2.5M	1.8M
Short Long Term Debt Total	203K	617K	4.8M	1.0M	1.2M	1.5M
Capital Lease Obligations	203K	617K	653K	1.0M	1.2M	1.2M
Inventory	(31.2M)	(12.2M)	1.2M	(229K)	(263.4K)	(276.5K)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Enlivex Stock Analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enlivex Historical Balance Sheet

Enlivex Therapeutics Inventory

(276,517)

About Enlivex Balance Sheet Analysis

Enlivex Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Enlivex Therapeutics balance sheet Correlations

Enlivex Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Enlivex Therapeutics balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Enlivex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Common Stock Shares Outstanding	+ 1.0	Common Stock
Common Stock Total Equity	+ 0.99	Common Stock
Common Stock Shares Outstanding	+ 0.98	Common Stock Total Equity
Long Term Debt	+ 0.97	Intangible Assets
Total Current Assets	+ 0.97	Cash And Short Term Investments

Preferred Stock Total Equity	- 1.0	Long Term Debt
Preferred Stock Total Equity	- 0.97	Intangible Assets
Net Debt	- 0.96	Cash
Other Stockholder Equity	- 0.95	Retained Earnings
Common Stock Shares Outstanding	- 0.88	Retained Earnings
Preferred Stock Total Equity	- 0.88	Good Will